Content
08/13/2024
Fremont, CA USA
Moximed
completed $91 million Series D Round funding. Investors include
Advent Life Sciences, Cormorant Asset Management, Future Fund, GBS Venture Partners, Morgenthaler, New Enterprise Associates, Vertex Ventures, Warren Point Capital.
About
Moximed's technology, the MISHA Knee System, is the result of over a decade of clinical research and development and is the first implantable shock absorber for the treatment of medial compartment knee osteoarthritis (OA). With experienced med-tech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss.
Startup
Sector:
MedTech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
